KRAS and neoplasm: As a further check, given that 15 out of the 50 H signatures are also contained in our informative collection, the fraction of H signatures present in both the output of the GSEA analysis and our informative compendium is evaluated: (i) colorectal cancer KRAS mutated vs. wild type 67%; (ii) colon cancer metastatic vs. primary 67 and 80% in RNA-seq and microarray, respectively; (iii) normal tissue vs. tumor in 4 tissues (lung 48%, gastric 47%, colon 44%, cervix 60%), and (iv) breast cancer late vs. early stage 33% TCGA and 87% METABRIC.